Targeting the SR-B1 receptor as a gateway for cancer therapy and tumor imaging
Malignant tumors display remarkable heterogeneity to the extent that even at the same tissue site different types of cells with varying genetic background may be found. In contrast, a relatively consistent marker the scavenger receptor type B1 (SR-B1) has been found to be consistently over expressed...
Main Authors: | Linda K Mooberry, Nirupama Avinash Sabnis, Bhavani Nagarajan, Marlyn Panchoo, Andras G Lacko |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00466/full |
Similar Items
-
The SR-B1 Receptor as a Potential Target for Treating Glioblastoma
by: Ethan Berney, et al.
Published: (2019-01-01) -
Reconstituted HDL: Drug Delivery Platform for Overcoming Biological Barriers to Cancer Therapy
by: Sangram Raut, et al.
Published: (2018-10-01) -
The role of cholesterol metabolism and cholesterol transport in carcinogenesis; A review of scientific findings, relevant to future cancer therapeutics.
by: Pedro Miguel Cruz, et al.
Published: (2013-09-01) -
HDL as a drug and nucleic acid delivery vehicle
by: Andras G Lacko, et al.
Published: (2015-10-01) -
SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer
by: Johnson R, et al.
Published: (2017-06-01)